TY  - JOUR
AU  - Cascinu, Stefano
AU  - Bodoky, György
AU  - Muro, Kei
AU  - Van Cutsem, Eric
AU  - Oh, Sang Cheul
AU  - Folprecht, Gunnar
AU  - Ananda, Sumitra
AU  - Girotto, Gustavo
AU  - Wainberg, Zev A
AU  - Miron, Maria Luisa Limon
AU  - Ajani, Jaffer
AU  - Wei, Ran
AU  - Liepa, Astra M
AU  - Carlesi, Roberto
AU  - Emig, Michael
AU  - Ohtsu, Atsushi
PY  - 2020
DO  - 10.1002/onco.13623
UR  - http://hdl.handle.net/10668/16731
T2  - The oncologist
AB  - In the intent-to-treat (ITT) population of the RAINBOW study, objective response rate (ORR) was 28% and 16% in the ramucirumab and control arms, respectively. To further characterize tumor response, we present details on timing and extent of tumor...
LA  - en
KW  - Gastric cancer
KW  - Gastroesophageal junction adenocarcinoma
KW  - Paclitaxel
KW  - Ramucirumab
KW  - Antibodies, Monoclonal, Humanized
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Humans
KW  - Paclitaxel
KW  - Quality of Life
KW  - Stomach Neoplasms
TI  - Tumor Response and Symptom Palliation from RAINBOW, a Phase III Trial of Ramucirumab Plus Paclitaxel in Previously Treated Advanced Gastric Cancer.
TY  - research article
VL  - 26
ER  -